Senate Bill Aims To Restrict Authorized Generics
U.S. Senate Democrats are reviving a proposal to restrict brand-name pharmaceutical companies' ability to market authorized generics during the 180-day exclusivity window following the first successful challenge to a brand patent...To view the full article, register now.
Already a subscriber? Click here to view full article